Treats T. vaginalis infection in females and males. ANDA 70033, held by PLIVA. Metronidazole.
As of Nov 21, 2026, ANDA 70033 (Metronidazole), held by PLIVA, was first approved by FDA on Dec 6, 1984, with 27 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 6, 1984 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole500MG · tablet;oral | Metronidazole | Rx |
| Oct 10, 2024 | Supplement 55Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 54Labeling · Standard review | Approved | None posted |
| Jun 20, 2024 | Supplement 53Labeling · Standard review | Approved | None posted |
| Mar 22, 2022 | Supplement 51Labeling · Standard review | Approved | None posted |
| Mar 22, 2022 | Supplement 47Labeling · Standard review | Approved | None posted |
| Aug 14, 2019 | Supplement 44Labeling · Standard review | Approved | None posted |
| Aug 14, 2019 | Supplement 43Labeling · Standard review | Approved | None posted |
| Sep 5, 2017 | Supplement 42Labeling · Standard review | Approved | None posted |
| Dec 24, 2014 | Supplement 37Manufacturing | Approved | None posted |
| Jul 21, 2014 | Supplement 41Labeling · Standard review | Approved | None posted |
| Sep 28, 2010 | Supplement 35Labeling | Approved | None posted |
| Oct 25, 2007 | Supplement 28Labeling | Approved | None posted |
| Jun 27, 2001 | Supplement 17Manufacturing | Approved | None posted |
| May 29, 2001 | Supplement 18Manufacturing | Approved | None posted |
| Jul 7, 2000 | Supplement 16Manufacturing | Approved | None posted |
| May 21, 1997 | Supplement 15Labeling | Approved | None posted |
| May 11, 1994 | Supplement 14Manufacturing | Approved | None posted |
| Jun 22, 1993 | Supplement 13Labeling | Approved | None posted |
| Sep 1, 1992 | Supplement 12Labeling | Approved | None posted |
| Oct 12, 1990 | Supplement 11Manufacturing | Approved | None posted |
| Oct 24, 1989 | Supplement 10Labeling | Approved | None posted |
| Apr 22, 1986 | Supplement 8Manufacturing | Approved | None posted |
| Jun 10, 1985 | Supplement 6Manufacturing | Approved | None posted |
| May 21, 1985 | Supplement 4Manufacturing | Approved | None posted |
| May 21, 1985 | Supplement 3Manufacturing | Approved | None posted |
| May 21, 1985 | Supplement 2Manufacturing | Approved | None posted |
| May 21, 1985 | Supplement 1Manufacturing | Approved | None posted |
| Dec 6, 1984 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters